MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting
Data from 76 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013 will be presented. Oral presentation will highlight MaaT013's potential in improving survival outcome for
United States Microbiotherapy Maa Florent Malard Drug Administration Early Access Program Trophic Communications
Source: finanznachrichten.de